Michael P. Dube's most recent trade in Intellia Therapeutics Inc was a trade of 2,503 Common Stock done at an average price of $10.0 . Disclosure was reported to the exchange on July 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | Michael P. Dube | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 9.95 per share. | 02 Jul 2025 | 2,503 | 57,137 (0%) | 0% | 10.0 | 24,905 | Common Stock |
| Intellia Therapeutics Inc | Michael P. Dube | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 14,000 | 59,640 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | Michael P. Dube | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 1,372 | 45,640 (0%) | 0% | 12.2 | 16,711 | Common Stock |
| Intellia Therapeutics Inc | Michael P. Dube | VP, Chief Accounting Officer | 02 Oct 2024 | 2,012 | 47,012 (0%) | 0% | 19.0 | 38,248 | Common Stock | |
| Intellia Therapeutics Inc | Michael P. Dube | VP, PAO and Interim PFO | 01 Jul 2024 | 17,801 | 49,024 (0%) | 0% | 0 | Common Stock |